Peer-reviewedCC BY-NC-ND 4.0Scientific Reports
Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
Related
- Association of Non‐Cytochrome P450 3A4‐Metabolized Statins Versus Atorvastatin With Major Adverse Cardiovascular Events in Patients With Cancer Receiving Tyrosine Kinase Inhibitors: A Propensity Score–Matched Target Trial Emulation
- Risk of de novo immune-related adverse events in patients with cancer and autoimmune disease receiving immune checkpoint inhibitors
- The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges
- High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors
- Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes
BibTeX
@article{alfehaid2026association,
title = {{Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors}},
author = {Lama Alfehaid and Ahmed S. Alanazi and Mansour Alomran and Hadi Skouri and Nada Alsuhebany},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74562-9},
url = {https://www.nature.com/articles/s41598-026-74562-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
AU - Lama Alfehaid
AU - Ahmed S. Alanazi
AU - Mansour Alomran
AU - Hadi Skouri
AU - Nada Alsuhebany
PY - 2026
DA - 2026/10/22
JO - Scientific Reports
DO - 10.1038/s41598-026-74562-9
UR - https://www.nature.com/articles/s41598-026-74562-9
SN - 2045-2322
ER -